Geisler J P, Wiemann M C, Miller G A, Geisler H E
Department of Obstetrics and Gynecology, St. Vincent Hospital and Health Care Center, Indianapolis, Indiana 46260, USA.
Gynecol Oncol. 1996 Mar;60(3):424-7. doi: 10.1006/gyno.1996.0067.
Steroid receptor status as a prognostic indicator in gynecologic malignancies has been a focus of study for almost 20 years. Although shown to be of importance in assessing prognosis in some patients with endometrial cancer, their importance in assessing prognosis in patients with serous cystadenocarcinoma of the ovary is not established.
All cases of stage IIIc serous cystadenocarcinoma of the ovary operated on by the gynecologic oncology service from January 1, 1981, through December 31, 1989, were evaluated for their estrogen and progesterone receptor status, time to recurrence, length of survival, and level of primary cytoreduction as well as FIGO stage, grade, and histology, Fresh tissue was obtained and frozen at the time of surgery for the steroid assays.
Ninety-six patients who had optimal primary cytoreductive surgery for their stage IIIc serous cystadenocarcinomas of the ovary and had their estrogen and progesterone receptor status established were found. Patients with an estrogen receptor level of less than or equal to 10 fmol/mg cytosol protein were shown to have a better mean survival (41 months) than patients with estrogen receptor levels greater than 10 fmol/mg cytosol protein (34 months) (P = 0.015). Five-year survival in the former group (38 patients) was 39.5% while 5-year survival in the latter group (58 patients) was 10.3% (P = 0.001). The was no correlation between progesterone status and survival (P > 0.05) in that same cohort of patients.
In patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary, an estrogen receptor level of less than or equal to 10 fmol/mg cytosol protein may be indicative of a better prognosis. Progesterone receptor status does not appear to affect survival.
类固醇受体状态作为妇科恶性肿瘤的预后指标，近20年来一直是研究的重点。尽管已证明其在评估某些子宫内膜癌患者的预后方面具有重要意义，但在评估卵巢浆液性囊腺癌患者的预后方面，其重要性尚未确立。
对1981年1月1日至1989年12月31日期间由妇科肿瘤服务团队进行手术的所有IIIc期卵巢浆液性囊腺癌病例，评估其雌激素和孕激素受体状态、复发时间、生存时长、初次肿瘤细胞减灭程度以及国际妇产科联盟（FIGO）分期、分级和组织学情况。手术时获取新鲜组织并冷冻，用于类固醇检测。
共发现96例接受了针对IIIc期卵巢浆液性囊腺癌的最佳初次肿瘤细胞减灭手术且其雌激素和孕激素受体状态得以确定的患者。雌激素受体水平小于或等于10 fmol/mg胞浆蛋白的患者，其平均生存期（41个月）比雌激素受体水平大于10 fmol/mg胞浆蛋白的患者（34个月）更长（P = 0.015）。前一组（38例患者）的5年生存率为39.5%，而后一组（58例患者）的5年生存率为10.3%（P = 0.001）。在同一组患者中，孕激素状态与生存之间无相关性（P > 0.05）。
在接受了最佳肿瘤细胞减灭的IIIc期卵巢浆液性囊腺癌患者中，如果雌激素受体水平小于或等于10 fmol/mg胞浆蛋白，则可能预示着较好的预后。孕激素受体状态似乎不影响生存。
